These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 10627750)
61. The role of screening for Helicobacter pylori in patients with duodenal ulceration in the primary health care setting. Rosengren H; Polson RJ Br J Gen Pract; 1996 Mar; 46(404):177-9. PubMed ID: 8731626 [TBL] [Abstract][Full Text] [Related]
62. [Characteristics of the effects of de-nol on the course of erosive-ulcerative lesions of the esophagus, stomach and duodenum associated with Helicobacter pylori]. Grebenev AL; Miagkova LP; Golochevskaia VS; Lapina TL; Sklianskaia OA Klin Med (Mosk); 1995; 73(2):34-7. PubMed ID: 7609414 [No Abstract] [Full Text] [Related]
64. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs. Langtry HD; Wilde MI Drugs; 1998 Sep; 56(3):447-86. PubMed ID: 9777317 [TBL] [Abstract][Full Text] [Related]
66. Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. McColl KE; Dickson A; El-Nujumi A; El-Omar E; Kelman A Am J Gastroenterol; 2000 Jan; 95(1):101-5. PubMed ID: 10638566 [TBL] [Abstract][Full Text] [Related]
67. [Helicobacter pylori and its role in gastric and duodenal ulcers]. Mach T Przegl Lek; 1995; 52(7):365-7. PubMed ID: 8525005 [No Abstract] [Full Text] [Related]
68. Multicenter evaluation of dual-therapy (omeprazol and amoxycillin) for Helicobacter pylori-associated duodenal and gastric ulcer (two years of the observation). Gabryelewicz A; Laszewicz W; Dzieniszewski J; Ciok J; Marlicz K; Bielecki D; Popiela T; Legutko J; Knapik Z; Poniewierka E J Physiol Pharmacol; 1997 Sep; 48 Suppl 4():93-105. PubMed ID: 9440060 [TBL] [Abstract][Full Text] [Related]
69. Interactions between Helicobacter pylori and gastroesophageal reflux disease. Yucel O Esophagus; 2019 Jan; 16(1):52-62. PubMed ID: 30151653 [TBL] [Abstract][Full Text] [Related]
70. The rationale of acid suppression in the treatment of acid-related disease. Mohamed AH; Hunt RH Aliment Pharmacol Ther; 1994; 8 Suppl 1():3-10. PubMed ID: 7910047 [TBL] [Abstract][Full Text] [Related]
71. The effect of eradicating helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Yokota K; Oguma K; Okada H; Shiratori Y Am J Gastroenterol; 2005 May; 100(5):1037-42. PubMed ID: 15842576 [TBL] [Abstract][Full Text] [Related]
78. [Recent view of gastro-esophageal reflux disease according to the guideline for gastric ulcer treatment]. Shirakawa K; Nakamura T; Masuyama H; Hiraishi H; Terano A Nihon Rinsho; 2004 Aug; 62(8):1559-64. PubMed ID: 15344551 [TBL] [Abstract][Full Text] [Related]
79. Helicobacter pylori and gastro-oesophageal reflux disease: association and clinical implications. To treat or not to treat with anti-H. pylori therapy? Loffeld RJ; van der Hulst RW Scand J Gastroenterol Suppl; 2002; (236):15-8. PubMed ID: 12408498 [TBL] [Abstract][Full Text] [Related]
80. Review article: is Helicobacter pylori status relevant in the management of GORD? Vigneri S; Termini R; Savarino V; Pace F Aliment Pharmacol Ther; 2000 Oct; 14 Suppl 3():31-42. PubMed ID: 11050485 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]